HCC treatment with Nexavar®
Nexavar® is an oral multikinase inhibitor for the treatment of hepatocellular carcinoma (HCC) and advanced renal cell carcinoma (RCC). Until now, patients with HCC have had limited treatment options. Nexavar® offers a new treatment option with proven clinical benefit for HCC.
Nexavar® mode of action
Nexavar® targets both the tumor cell and tumor vasculature. In preclinical studies, Nexavar® has been shown to target members of two classes of kinases known to be involved in both cell proliferation (growth) and angiogenesis (blood supply) – two important processes that enable cancer growth.